Logo

As Expected, ABI Completes Equity Investment in VisiGen

Dec 09, 2005

NEW YORK, Dec. 9 (GenomeWeb News) - Applied Biosystems said yesterday that it has completed its equity investment in VisiGen Biotechnologies.

 

ABI announced its plans to invest in the company, which is developing next-generation sequencing technology, in October.

 

ABI has also entered into a scientific collaboration with VisiGen.

 

Financial terms of the transaction was not disclosed, although ABI's investment hinged on a follow-on investment from VisGen shareholder SeqWright.

 

SeqWright announced that it had made a second equity investment, of an undisclosed amount, in November.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.